LifeLabs® EMPOWERING HEALTHIER CANADIANS FOR OVER 60 YEARS

A game-changer in MRD testing: predicting which patients will benefit from treatment escalation in colorectal cancer

Overview

- Despite optimal surgery and adjuvant chemotherapy, 20-60% of stage III CRC patients will have recurrence of disease
- Better strategies are needed to reduce risk of recurrence and improve survival in stage III CRC
- Signatera™ MRD testing was used to determine if a subgroup of patients may benefit from the addition of celecoxib

Study schema



Survival by Signatera™ ctDNA status

Disease-free survival



ctDNA status	Events / Total	HR (95% CI)	3y estimate (95% CI)
Negative	131/767	Reference	86.5 (84.0-89.1%)
Positive	118/173	7.14 (5.54-9.21)	33.7 (27.1-41.8%)

Log-rank *P*-value < 0.0001

Overall survival



ctDNA status	Events / Total	HR (95% CI)	3y estimate (95% CI)
Negative	77/767	Reference	91.5 (89.5-93.6%)
Positive	85/173	6.72 (4.91-9.18)	52.6 (45.3-61.0%)

Log-rank *P*-value < 0.0001

Signatera™ MRD status after surgery and prior to starting adjuvant therapy was highly prognostic of DFS and OS

Signatera™-positive patients treated with both chemotherapy and celecoxib showed a 40% improvement in overall survival compared to chemotherapy alone



Assigned oral agent by ctDNA status	Events / Total	HR (95% CI)	5y estimate (95% CI)
Negative			
Celecoxib	36/375	0.86 (0.55-1.35)	91.8 (88.9-94.7%)
Placebo	41/392	Reference	91.3 (88.4-94.3%)
Log-rank *P*-value = 0.5098			
Positive			
Celecoxib	41/99	0.58 (0.38-0.90)	61.6 (52.4-72.4%)
Placebo	57/74	Reference	39.9 (29.6-53.8%)
Log-rank *P*-value = 0.0135			
Likelihood-Ratio interaction *P*-value: 0.2061			

Why this matters

Results suggest a potential role for Signatera™ ctDNA testing in determining which stage III patients should consider celecoxib in addition to standard of care FOLFOX adjuvant therapy

Questions to consider

- How do you determine which stage III patients would benefit from treatment escalation?
- How does this data impact your thoughts on how Signatera™ can be used to help guide treatment decisions in stage III patients?

Scan to read the publication

Discover more at **lifelabs.com/signatera**

References:
1. Jonathan A. Nowak, MD, PhD et al. Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702, as presented at the 2025 American Society of Clinical Oncology's Gastrointestinal Cancers Symposium (ASCO GI)

LifeLabs® EMPOWERING HEALTHIER CANADIANS FOR OVER 60 YEARS

AUTHORIZED DISTRIBUTOR

natera™ | Signatera™ Residual disease test (MRD)